Nov 14, 2022 8:05am EST Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614
Oct 31, 2022 8:05am EDT Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product
Oct 28, 2022 9:40am EDT Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study
Oct 12, 2022 8:05am EDT Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference
Sep 22, 2022 8:05am EDT Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR
Sep 21, 2022 8:05am EDT Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022
Aug 31, 2022 11:55am EDT Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose